MIF and lung adenocarcinoma: More recent studies demonstrate that MIF and D-DT additively antagonize the tumor suppressive activities of AMP-activated protein kinase (AMPK) in lung adenocarcinoma cells resulting in maximal mTOR pathway activation [15].